The Startup That Manipulated Data to Get a Miracle Drug to Market
September 16, 2019
(Wall Street Journal) – The startup had something incredible: a cure for babies with a deadly neurological disease. Last year, the company was snapped up by pharmaceutical giant Novartis AG NVS -0.98% , and by this past May, its drug was the most expensive on the market. In just a few years, the company, AveXis Inc., morphed from a handful of hospital-based researchers into one of the pharmaceutical industry’s most stunning success stories. But in the hurry to fulfill the drug’s promise, AveXis manipulated data that went into the drug’s approval, Novartis and the Food and Drug Administration now say.